Clinical trials: Community-acquired Pneumonia, open to volunteers
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism)…
- Conditions
- Pneumonia, Community-Acquired, COVID-19 Pneumonia, Cardiovascular Diseases
- Trial name
- HOMI-LUNG CAP (NCT06601998)
- Testing
- Blood samples and Oropharyngeal swab, Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- Where
- 19 sites in Greece
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Community Acquired Pneumonia (CAP)
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive…
- Trial name
- DC-CAP (NCT07537413)
- Testing
- Ceftriaxone 1 gram daily, Ceftriaxone 2 grams daily
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- University of Maryland, Baltimore
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Sepsis
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with…
- Trial name
- CLASSIFY (NCT07834346)
- Testing
- clarithromycin
- Where
- 19 sites in Greece
- Volunteers
- 252 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Bronchitis, Acute, Community-acquired Pneumonia
Multimodal Stewardship Programme to Improve Antibiotic Prescribing for Children With Lower Respiratory Tract Infections
Children with lower respiratory tract infection (LRTI) are still often prescribed antibiotics in ways that depart from national guidelines.
- Conditions
- Bronchitis, Acute, Community-acquired Pneumonia, Respiratory Tract Infections
- Trial name
- PRACTICE-LRTI (NCT07893834)
- Testing
- PRACTICE-LRTI multimodal antimicrobial stewardship programme
- Where
- Finland
- Volunteers
- 50,000 people
- Sponsor
- Tampere University
Multi Drug Resistant Infections, Pneumnia
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
This is a multicenter prospective observational cohort study involving hospitalized adult patients with multidrug-resistant bacterial pneumonia.
- Trial name
- MDRBP-TCM (NCT07726095)
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Community-acquired Pneumonia
Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics
Children are commonly hospitalized because of community-acquired pneumonia. Despite the fact that many of these children have viral disease, a majority is treated with antibiotics.
- Trial name
- PRESTO-1 (NCT06114888)
- Testing
- MeMed BV + Usual Care, Usual Care Alone
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Jeffrey Pernica
Community Acquired Pneumonia (CAP)
Chest Radiography Versus Ultra-Low-Dose Chest Computed Tomography in Adults in the Emergency Department
Objective: To quantify and compare total staff person-time per imaging episode betweenconventional chest radiography (CXR) and ULDCT in adult emergency department patients in whom CAP is a differential diagnosis.
- Trial name
- TIME-CAP (NCT07870525)
- Testing
- ULDCT
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Southern Denmark
Community-acquired Pneumonia
AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeutic-dose heparin vs.
- Trial name
- ATTACC-CAP (NCT05848713)
- Testing
- Heparin
- Where
- 68 sites in United States, Brazil and 2 more
- Volunteers
- 4,000 people
- Sponsor
- University of Manitoba
Community-acquired Pneumonia
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
The purpose of this study is to compare effectiveness and safety of Azithromycin versus Doxycycline in adult patients hospitalized with community acquired pneumonia (CAP) treated with Beta-lactams.
- Trial name
- AD-CAP (NCT07164131)
- Testing
- Doxycycline, Azithromycin
- Where
- 5 sites in United States
- Volunteers
- 1,120 people
- Sponsor
- Mayo Clinic
Community-acquired Pneumonia, Community-Acquired Infections
Noninvasive Support Methods for Acute Respiratory Failure of Community-acquired Pneumonia
This randomized controlled trial aims to compare the efficacy and safety of high-velocity nasal insufflation (HVNI) versus standard noninvasive ventilation (NIV) in adult patients experiencing acute exacerbations of…
- Trial name
- NCT06996834
- Testing
- Non-Invasive ventilation (NIV), High Velocity Nasal Insufflation
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Community Acquired Pneumonia in Children, Antibiotic Stewardship
Antibiotic Prescription in Children Hospitalized for Community-acquired Pneumonia
A study to observe how often antibiotics are prescribed in children hospitalized for pneumonia and how doctors decide if a child needs antibiotics or not. Parent satisfaction will also be recorded.
- Trial name
- NCT04681339
- Testing
- Antibiotic treatment, No antibiotic treatment
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- ARCIM Institute Academic Research in Complementary and Integrative Medicine
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Community-acquired Pneumonia (CAP)
TCM Cohort for Elderly CAP
This study evaluates the real-world clinical efficacy of traditional Chinese medicine (TCM) in elderly Community-acquired pneumonia (CAP) patients and explores syndrome characteristics and their associations with biomarkers.
- Trial name
- NCT07797686
- Testing
- Traditional Chinese medicine (TCM), Non-traditional Chinese medicine (non-TCM)
- Where
- China
- Volunteers
- 2,234 people, healthy volunteers welcome
- Sponsor
- Henan University of Traditional Chinese Medicine
Community-Acquired Pneumonia (CAP)
Lefamulin Post-Market Surveillance Study
Community-acquired pneumonia (CAP) refers to infectious parenchymal lung inflammation acquired outside hospital settings. In China, its incidence is 7.13 per 1000 person-years, with over 10 million new cases annually.
- Trial name
- NCT07697885
- Testing
- This is a multicenter, single-arm, non-interventional study. No interventional measures will be adopted.
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Influenza, Community-acquired Pneumonia
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain…
- Conditions
- Influenza, Community-acquired Pneumonia, Cardiovascular Events
- Trial name
- NCT06029933
- Testing
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
- Where
- United States
- Volunteers
- 1,500,000 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Pneumonia, Viral, Ventilator Associated Pneumonia
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her/his life.
- Conditions
- Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex
- Trial name
- HerpMV (NCT06134492)
- Testing
- Acyclovir
- Where
- 28 sites in Germany
- Volunteers
- 616 people
- Sponsor
- Jena University Hospital
Pneumonia, Fungal Pneumonia
Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score
The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.
- Conditions
- Pneumonia, Fungal Pneumonia, Aspergillosis Pneumonia, Pulmonary Aspergillosis
- Trial name
- FUNGAL-P (NCT07681583)
- Testing
- FUNGAL-P Score Assessment
- Where
- Italy
- Volunteers
- 400 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Community-Acquired Pneumonia
Community-acquired Pneumonia Due to Chlamydia Pneumoniae
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C.
- Trial name
- CHLAMPAC (NCT07679789)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de Saint-Denis
Community Acquired Pneumonia, Childhood Pneumonia
3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT
Pneumonia is the most common infection in children and leading to most common cause of mortality and morbidity in in children globally. Bacterial cause is mostly streptococcus pneumonia in children of 3 months to 5 years of age.
- Trial name
- Pnemonia (NCT07647835)
- Testing
- Amoxicillin
- Where
- Pakistan
- Volunteers
- 250 people
- Sponsor
- Khyber Teaching Hospital